<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16662">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889978</url>
  </required_header>
  <id_info>
    <org_study_id>GRAIL-001</org_study_id>
    <nct_id>NCT02889978</nct_id>
  </id_info>
  <brief_title>The Circulating Cell-free Genome Atlas Study</brief_title>
  <acronym>CCGA</acronym>
  <official_title>The Circulating Cell-free Genome Atlas Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GRAIL, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GRAIL, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop
      assays to detect cancer early in blood. The purpose of this study is to collect biological
      samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors
      who do not have a diagnosis of cancer (blood) in order to characterize the population
      heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing
      cancer from non-cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, observational study with collection of de-identified
      biospecimens and clinical data from at least 10,000 participants from clinical networks in
      the United States. The study will enroll at least 7000 cancer subjects with multiple solid
      tumor types (the CANCER arm) and at least 3000 representative subjects without a clinical
      diagnosis of cancer (the NON-CANCER arm). Cancer subjects with a new diagnosis and no prior
      systemic therapy will be recruited. Clinical data relevant to cancer status are collected
      from all participants and their medical record at baseline, and subsequently from the
      medical record at intermittent future time points, at least annually for up to 5 years. The
      study test(s) to be used in this protocol are next generation sequencing (NGS)-based
      assay(s) that are under investigation and development at GRAIL.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of histologically confirmed cancer in subjects with circulating tumor DNA (ctDNA) detected by deep sequencing.</measure>
    <time_frame>18 months</time_frame>
    <description>Clinically annotated plasma samples from cancer and non-cancer subjects will undergo deep sequencing to characterize cfNA profiles and to estimate the population heterogeneity in the two arms of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of genomic variants detected in plasma cfNA in cancer subjects who also have available tumor tissue.</measure>
    <time_frame>18 months</time_frame>
    <description>Concordance of variants identified in sequencing plasma cfNA and tumor tissue from the same subject will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival or clinical cancer status (none, mild, moderate, or severe) of all subjects with results from deep sequencing plasma cfNA.</measure>
    <time_frame>Year 1, 2, 3, 4, 5</time_frame>
    <description>Explore the relationship between genomic results and clinical outcomes based on collection of longitudinal information (at least annually for up to 5 years) from medical records.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Neoplasms</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cancer arm</arm_group_label>
    <description>Subjects with new diagnosis of cancer (multiple tumor types) from which a blood sample and contemporaneous FFPE tumor tissue will be collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-cancer arm</arm_group_label>
    <description>Subjects with no known diagnosis or past history of cancer from which a blood sample will be collected.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, white blood cells, formalin fixed, paraffin embedded (FFPE) tumor tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible study subjects will be recruited from participating medical centers in a ratio of
        3 non-cancer subjects for every 7 cancer subjects within each center. Non-cancer subject
        recruitment will be monitored to achieve demographic characteristics (eg, age, gender,
        ethnicity, smoking status) reflective of those of the cancer subjects.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20 years or older

          -  Able to provide a written informed consent and who understand and agree to all study
             procedures required

        Cancer group:

          -  Either of the following:

          -  New diagnosis of histologically confirmed cancer (any stage I-IV, as well as
             carcinoma in situ (CIS)), across multiple solid tumor types with no prior systemic
             cancer therapy and scheduled for surgical resection or non-surgical management

          -  Or, Subjects with a high suspicion for cancer diagnosis by clinical and radiological
             assessment, but without preceding histologic diagnosis, are eligible, if they have
             not received prior systemic cancer therapy and are scheduled for surgery

          -  Has or will have a medically obtained pathological tumor specimen from core needle or
             surgical biopsy and/or surgical resection within 4 weeks (28 days) of study blood
             draw and pre-treatment

        Non-Cancer group:

        ‚óè At least one guideline recommended cancer screening test documented in the medical
        record, if indicated for age and gender (eg, pap smear, mammography, and/or colonoscopy)

        Exclusion Criteria:

          -  Prior diagnosis of cancer except: non-melanomatous skin cancer

          -  Pregnancy (by self-report of pregnancy status)

          -  Current febrile illness or active inflammatory disease

          -  Poor health status or unfit to tolerate blood draw
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy J Sehnert, MD</last_name>
    <role>Study Director</role>
    <affiliation>GRAIL, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy J Sehnert, MD</last_name>
    <email>asehnert@grailbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alan H Bryce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie J Donnachaidh</last_name>
      <phone>303-418-7639</phone>
    </contact>
    <investigator>
      <last_name>Allen L Cohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie J Donnachaidh</last_name>
      <phone>303-385-2000</phone>
    </contact>
    <investigator>
      <last_name>Allen L Cohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie J Donnachaidh</last_name>
      <phone>719-577-2555</phone>
    </contact>
    <investigator>
      <last_name>Allen L Cohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie J Donnachaidh</last_name>
      <phone>303-388-4876</phone>
    </contact>
    <investigator>
      <last_name>Allen L Cohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie J Donnachaidh,</last_name>
      <phone>303-321-0302</phone>
    </contact>
    <investigator>
      <last_name>Allen L Cohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue A Speyer</last_name>
      <phone>303-430-2700</phone>
    </contact>
    <investigator>
      <last_name>Allen L Cohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120-4413</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie J Donnachaidh</last_name>
      <phone>303-730-4700</phone>
    </contact>
    <investigator>
      <last_name>Allen L Cohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie J Donnachaidh</last_name>
      <phone>303-925-0700</phone>
    </contact>
    <investigator>
      <last_name>Allen L Cohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie J Donnachaidh</last_name>
      <phone>303-684-1900</phone>
    </contact>
    <investigator>
      <last_name>Allen L Cohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Parker</city>
        <state>Colorado</state>
        <zip>80138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie J Donnachaidh</last_name>
      <phone>303-805-7744</phone>
    </contact>
    <investigator>
      <last_name>Allen L Cohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <zip>81008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie J Donnachaidh</last_name>
      <phone>719-296-6000</phone>
    </contact>
    <investigator>
      <last_name>Allen L Cohn, MDe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie J Donnachaidh</last_name>
      <phone>303-386-7622</phone>
    </contact>
    <investigator>
      <last_name>Allen L Cohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hartford HealthCare Cancer Institute</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester at Deerfield Beach</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33442</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mikhail</last_name>
      <phone>305-243-6855</phone>
    </contact>
    <investigator>
      <last_name>Johnathan C Trent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester at Hollywood</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mikhail</last_name>
      <phone>305-243-6855</phone>
    </contact>
    <investigator>
      <last_name>Johnathan C Trent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexander S Parker, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester at Kendall</name>
      <address>
        <city>Kendall</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mikhail</last_name>
      <phone>305-243-6855</phone>
    </contact>
    <investigator>
      <last_name>Johnathan C Trent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mikhail</last_name>
      <phone>305-243-6855</phone>
    </contact>
    <investigator>
      <last_name>Johnathan C Trent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester at Plantation</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mikhail</last_name>
      <phone>305-243-6855</phone>
    </contact>
    <investigator>
      <last_name>Johnathan C Trent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tonya Gardner, CCRC</last_name>
    </contact>
    <investigator>
      <last_name>Daron Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Kelly, RN, BSN, OCN</last_name>
    </contact>
    <investigator>
      <last_name>Wangjian Zhong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daron Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Paducah</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betty Kuiper, PhDc, MSN</last_name>
    </contact>
    <investigator>
      <last_name>Nicholas Lopez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daron Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Minnesota</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Minetta Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fergus Couch, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Research - Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pearlena Hamlet</last_name>
    </contact>
    <investigator>
      <last_name>Mohan Tummala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patti Baucco</last_name>
      <phone>216-445-2164</phone>
      <email>CCGAstudy@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Eric Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C. dba Compass Oncology</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213-2982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret E Bigler</last_name>
      <phone>503-231-2612</phone>
    </contact>
    <investigator>
      <last_name>David A Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C. dba Compass Oncology</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan R Papenfuse</last_name>
      <phone>503-291-6233</phone>
    </contact>
    <investigator>
      <last_name>David A Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C. dba Compass Oncology</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary McCormick</last_name>
      <phone>503-528-5005</phone>
    </contact>
    <investigator>
      <last_name>David A Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C. dba Compass Oncology</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna R Cunningham</last_name>
      <phone>503-885-5411</phone>
    </contact>
    <investigator>
      <last_name>David A Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Saint Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Lowery, RN, BSN</last_name>
    </contact>
    <investigator>
      <last_name>Robert Siegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional Healthcare System</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Kuenzli, RN</last_name>
      <phone>864-560-7579</phone>
      <email>kkuenzli@gibbscc.org</email>
    </contact>
    <contact_backup>
      <last_name>Darla Howard, RN</last_name>
      <phone>864-560-1042</phone>
      <email>dhoward@srhs.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rosanna Lapham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Amarillo Cancer Center</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John R McMahan</last_name>
      <phone>806-358-8654</phone>
    </contact>
    <investigator>
      <last_name>Leonardo Forero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Presbyterian Cancer Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Barter</last_name>
      <phone>214-265-2080</phone>
    </contact>
    <investigator>
      <last_name>Kristi J McIntyre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Lopez</last_name>
      <phone>214-370-1000</phone>
    </contact>
    <investigator>
      <last_name>Carlos H Roberto Becerra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Longview Cancer Center</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly K Maxfield</last_name>
      <phone>903-757-2122</phone>
    </contact>
    <investigator>
      <last_name>Donald A Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly K Maxfield</last_name>
      <phone>903-579-9800</phone>
    </contact>
    <investigator>
      <last_name>Donald A Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C. dba Compass Oncology</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan R Papenfuse</last_name>
      <phone>360-449-6521</phone>
    </contact>
    <investigator>
      <last_name>David A Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 23, 2017</lastchanged_date>
  <firstreceived_date>August 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer Screening</keyword>
  <keyword>High-Throughput Nucleotide Sequencing</keyword>
  <keyword>Deep Sequencing</keyword>
  <keyword>Circulating cell-free tumor DNA</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
